Estimation of thyroid profile in patients with diabetes mellitus in New Civil Hospital, Surat

Background: Diabetes mellitus (DM) and thyroid diseases are the two common endocrinopathies seen commonly in the population. There is inter-dependence between insulin and thyroid hormones for normal cellular metabolism so that DM and thyroid diseases can mutually influence the other disease process. The excess or deficit of one hormone may result in functional derangement of other. Diabetes being a most common endocrine metabolic disorder, the variety of thyroid abnormalities may co-exist and interact with DM. Early detection of thyroid dysfunction and its treatment can delay the long-term complications of DM. The present study was planned to determine prevalence of thyroid dysfunction in DM patients and therefore to provide the appropriate guidelines.Methods: The study was cross-sectional. 100 patients were enrolled for the study. Among them 50 were control (non-diabetic) and 50 were cases (diabetic). They were enrolled in the study from medicine outpatient department’s and inpatient department’s according to inclusion and exclusion criteria. Their thyroid profile (free T3, T4 and thyroid stimulating hormone) was done by chemiluminescence assay method.Results: Results were analyzed by unpaired-t-test. Prevalence of thyroid dysfunction was found significantly high in DM patients. p<0.05 value considered as statistically significant.Conclusions: Screening for thyroid disease among patients with diabetes mellitus should be routinely performed for early detection and treatment of thyroid dysfunction to delay the complications of diabetes

Study of effects of metformin on C-reactive protein level in Type-2 diabetes mellitus

Background: Diabetes mellitus (DM) is extremely common; represent a significant global health problem. Type-2 DM is considered to be associated with a low grade inflammation, which may play a significant role in development of cardiovascular complications evidenced by C-reactive protein (CRP) is a an extremely sensitive marker of systemic inflammation. The study was undertaken to check the effect of metformin on CRP level in Type-2 DM.Methods: The study was prospective and non-randomized. Thirty newly diagnosed Type-2 DM selected for metformin therapy by medicine personnel were enrolled in the study based on inclusion and exclusion criteria. Patients were divided into pre-treatment (before starting metformin therapy) and post-treatment group. Fasting blood sugar (FBS), postprandial blood sugar (PP2BS), CRP level were measured at the time of enrolment and 3 months after starting metformin monotherapy.Results: Results were analyzed using pair t-test. Metformin therapy was found to decrease CRP level significantly along with FBS, PP2BS level. p<0.05 value considered as statistically significant. Value was expressed as mean ± standard deviation.Conclusions: Treatment with 3 months metformin monotherapy for newly diagnosed Type-2 DM has shown a significant decrease in high-sensitivity-CRP level in Type 2 diabetes. This positive effect may be because of the decreased in the expression of proinflammatory cytokines and other mediators, including adhesion molecules, suggests that these processes may contribute to atherogenesis because atherosclerosis is also an inflammatory condition. However, this effect is probably dependent on improving glycemic control

Effect of atenolol on hemoglobin level in mild to moderate hypertension

Background: Hypertension is the most common cardiovascular disease and a major cardiovascular risk factor that causes significant morbidity and mortality worldwide. Most common type is primary (essential) hypertension and is genetically determined. It affects many systems of the body and can also alter various hematological parameters. The study was undertaken to check the effect of atenolol on hemoglobin (Hb) level in mild to moderate hypertension.Methods: The study was prospective and non-randomized. Thirty newly diagnosed hypertensives selected for atenolol therapy by medicine personnel were enrolled in the study based on inclusion and exclusion criteria. Patients were divided into pre-treatment (before starting atenolol therapy) and post-treatment group. Red blood cell (RBC) count, Hb, packed cell volume (PCV) and red cell indices were measured at the time of enrolment and then monthly after starting atenolol for next 3 months.Result: Results were analyzed by repeated measure analysis of variance. Atenolol treatment was found to increase Hb and PCV significantly, whereas no significant change in RBC count and red cell indices.Conclusions: Treatment with atenolol for mild to moderate hypertension has shown a significant increase in Hb and PCV level. This positive effect may be because of the decrease in sodium and water reabsorption by decrease in sympathetic overactivity and excretion of sodium and water by improvement in kidney functions. Atenolol has no any direct effect on Hb synthesis and erythropoiesis